Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Berinert P: Phase III data

In the double-blind, international Phase III IMPACT trial in 125 patients, the higher of 2 doses of C1-INH (20

Read the full 196 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE